Loading company…
Santero Therapeutics develops antibiotics for infections caused by multidrug-resistant bacteria.
Founded in 2021 as a spin-off from Université libre de Bruxelles, Santero Therapeutics develops antibiotics for multidrug-resistant infections, targeting Gram-negative bacteria. In June 2023, it raised EUR 8 million in Series A funding led by Newton Biocapital Partners, with Belgium Federal Holding Company, Sambrinvest, and Wallonie Entreprendre participating. The company is based in Belgium and plans to use the funding for antibiotic development and research.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in